

Special Issue

Targeting the Tumor Microenvironment in Blood Cancer

Message from the Guest Editors

To date, it is widely established that the tumor microenvironment plays a pivotal role in the development of blood cancers, sustaining tumor progression, angiogenesis, immune suppression, and drug resistance. Increasing studies are currently investigating novel “players” (e.g. cytokines, deregulated pathways, immune system, epigenetics, miRNAs, extracellular vesicles, and, metabolites) involved in the mutual crosstalk that remodel the tumor milieu, creating a pro-survival niche. Therefore, targeting the tumor microenvironment represents an attractive strategy to enhance the efficacy of tumor-targeting drugs and to prevent pharmacological escape, improving patients’ outcome. This Special Issue will focus on the novel preclinical and clinical therapeutic strategies able to target the tumor microenvironment in order to overcome its protective effect in hematological malignancies. For this Special Issue, authors are encouraged to submit original research, systematic reviews, and review articles.

Guest Editors

Dr. Ilaria Saltarella

Dr. Concetta Altamura

Dr. Paola Poma

Deadline for manuscript submissions

closed (15 June 2025)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/206860

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)